MedTrace Logo

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2026-05-19

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)

Interventions

DRUG

Aflibercept Injection

Aflibercept administered as a 2 milligram (mg) intravitreal injection

DRUG

Sham procedure

Needleless syringe used to simulate an intravitreal injection

DRUG

AR-14034 SR implant

AR-14034 SR administered as an intravitreal implant

DRUG

AR-14034 SR implant higher dose

AR-14034 SR administered as an intravitreal implant

DRUG

AR-14034 SR implant lower dose

AR-14034 SR administered as an intravitreal implant

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Director of Clinical Development, Alcon · Alcon Research, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-06
Primary Completion
2027-10-31
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05769153 on ClinicalTrials.gov